KVISTGAARD, Denmark, April 7, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated data from an NCI sponsored combination study of Bavarian Nordic’s active immunotherapy candidate PROSTVAC and ipilimumab will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Wednesday, April 9, 2014. The data highlights the potential synergy of combining PROSTVAC with an immune checkpoint inhibitor.
Help employers find you! Check out all the jobs and post your resume.
